VideoTuberculosisA new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MDView Video
VideoTuberculosisRifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhDView Video
VideoTuberculosisRifampin vs. Rifapentine: a debate over the preferred rifamycin | Charles Peloquin, PharmDView Video
VideoTuberculosisLong acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSBView Video
VideoHIVViral Hepatitis and Liver DiseaseOther Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika | Steven Kern, PhDView Video
VideoHIVViral Hepatitis and Liver DiseaseThe FDA Perspective on Hepatitis C Drug Resistance | Patrick Harrington, PHDView Video
VideoHIVViral Hepatitis and Liver DiseaseLooking Backwards: Hormonal Contraception and ART | Kimberly Scarsi, PharmD, MS, FCCPView Video
VideoHIVViral Hepatitis and Liver DiseasePharmacogenetics - Back to reality | Andrew Owen, BSS, MSC, PhD, FSBView Video
VideoHIVViral Hepatitis and Liver DiseaseWill we see the Back of DDIs? | Catia Marzolini, PharmD, PhDView Video
VideoHIVViral Hepatitis and Liver DiseaseThe ‘Back Side’ of Compartments | Saye Khoo, MD, PhDView Video
VideoHIVViral Hepatitis and Liver DiseaseBack-terial co-infections | Mohammed Lamorde, FRCP, PhDView Video
VideoHIVViral Hepatitis and Liver DiseaseBacking up clinical data with modelling | Marco Siccardi, PhDView Video
VideoHIVViral Hepatitis and Liver DiseaseSpecific Complex Interactions (mechanic presentation) | David Burger, PharmD, PhDView Video
